Reuters logo
BRIEF-Protagonist Therapeutics announces preliminary phase 1 study results with PTG-300
September 20, 2017 / 12:26 PM / in 3 months

BRIEF-Protagonist Therapeutics announces preliminary phase 1 study results with PTG-300

Sept 20 (Reuters) - Protagonist Therapeutics Inc

* Protagonist Therapeutics announces preliminary phase 1 study results with novel hepcidin mimetic, PTG-300

* Protagonist Therapeutics Inc - ‍expect to report final top line results of amended PTG-300 study in Q4 of 2017​

* Protagonist - ‍PTG-300 showed dose-dependent increase in blood exposure, was well tolerated, with no serious adverse events or dose-limiting toxicities​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below